Compare Eli Lilly And Co (LLY) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sirius XM Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Sirius XM Holdings Inc trades at $26.61 (market cap $8.87B). The key difference: Eli Lilly And Co is far larger — about 117.2× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (4.1%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Sirius XM Holdings Inc for 102 Days on average.
| LLY | SIRI | |
|---|---|---|
Market Cap | $1.04T | $8.87B |
Volume | 3,064,878 | 4,324,672 |
Sector | Health | Media |
52-Week High | $1.28K | $32.59 |
52-Week Low | $799.57 | $19.92 |
Typical Hold Time | 93 Days | 102 Days |
Enterprise Value | $1.09T | $18.16B |
Dividend Yield | 0.59% | 4.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Sirius XM (SIRI) trades at $26.67, up 2.77% today, with mixed technical signals showing neutral momentum. The stock shows attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, while recent earnings have been inconsistent with two misses and one beat in the last three quarters. The company maintains solid profitability with 47.36% gross margins and positive cash flow generation, supported by recent strategic initiatives including YouTube partnerships and advertising expansion.
The investment case balances value appeal against execution risks. Analyst consensus remains bullish with a $34.43 price target (29% upside), though investors face risks from competitive pressures and inconsistent earnings performance. The company's strong cash flow and strategic partnerships provide growth catalysts, but requires monitoring of subscription trends and advertising revenue execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
